Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14974864 | 1.00 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL14974296 | 1.00 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL14974010 | 0.89 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL14973926 | 0.87 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL14973928 | 0.87 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL14974161 | 0.87 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL16212110 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL14973713 | 0.83 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL14911341 | 0.82 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL14911342 | 0.82 | CNR2 (0.74) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | claimed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | claimed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | claimed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013076182-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TBXA2R, TYMP | CNR2 135/4885CNR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.